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Summary. Intracranial tumours such as brain gliomas 
and pituitary adenomas pose a challenging area of 
research for the development of gene therapy strategies, 
both from the point of view of the severity of the 
diseases, to the physiological implication of gene 
delivery into the central nervous system and pituitary 
gland. On the one hand, brain gl iomas are very 
malignant tumours, with a life expectancy of six months 
to a year at the most after the time of diagnosis, in spite 
of advances in treatment modalities which involve 
chemotherapy, surgery and radiotherapy. Gene therapy 
for these tumours is therefore a very attractive 
therapeutic modality which due to the severity of the 
disease is already in clinical trials. On the other hand, 
pituitary tumours are usually benign, and in most cases, 
treatment is successful. Nevertheless, there are some 
instances, especially with the macroadenomas and some 
invasive tumours in which treatment fails. Gene therapy 
strategies for these adenomas therefore needs to progress 
substantially in terms of safety, adverse side effects and 
physiological impact on the normal pituitary gland 
before clinical implementation. 
In this paper, we will review gene delivery systems 
both viral and non-viral and several therapeutic 
strategies which could be implemented for the treatment 
of these diseases. These include cytotoxic approaches 
both conditional and direct,  immune-stimulatory 
strategies, anti-angiogenic strategies and approaches 
which harness pro-apoptotic and tumour suppressor gene 
targets. We will also review the models which are 
currently available in which these gene therapy 
strategies can be tested experimentally. 
This new therapeutic modality holds enormous 
promise, but we still need substantial improvements both 
from the delivery, efficacy and safety stand points before 
it can become a clinical reality. 
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Introduction 
Although gene therapy was first envisaged for the 
treatment of genetically inherited disorders such as 
hemophilia,  cystic fibrosis and severe combined 
immunodeficiency syndrome, the majority of gene 
therapy studies currently underway are for the treatment 
of acquired diseases such as  AIDS, cancer  and 
cardiovascular disorders. Currently, 72% of gene therapy 
clinical trials are  for  the treatment of cancer  
(Lowenstein, 1997). The main reasons for this are that 
the therapeutic endpoints for the treatment and the 
population of cells which needs to be targeted are very 
well defined. In general, for the successful treatment of 
cancer, the required duration of transgene expression 
could be relatively short (i.e. sufficient to kill the tumour 
cells) compared to that required to treat inherited genetic 
disorders.  Also because of the relatively rapid 
progression of most tumours, it is possible to monitor the 
clinical outcome of the treatment over a relatively short 
period. The availability of a large cohort of patients with 
severe and life threatening acquired diseases, such as 
cancer and AIDS, provides a clinical scenario in which 
to develop and test new strategies for gene delivery and 
therapy that might be applied later for inherited diseases 
(Martin Duque et al., 1998) 
For cancer treatment the goal of gene therapy would 
be to induce tumour cell killing andlor induce anti- 
tumour immune responses (Lowenstein, 1997; Castro, 
1999; Castro et al., 1999; Lowenstein et al., 1999). 
Below we will review several gene transfer and anti- 
tumour strategies, as well as disease models, in which to 
assess the efficiency of these novel therapeutic 
modalities, with special emphasis on intracranial 
tumours, i.e. gliomas and pituitary adenomas. 
In vivo gene transfer vehicles 
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